MA59115A1 - Camptothecin analogues conjugated to a glutamine residue in a protein and their use - Google Patents

Camptothecin analogues conjugated to a glutamine residue in a protein and their use

Info

Publication number
MA59115A1
MA59115A1 MA59115A MA59115A MA59115A1 MA 59115 A1 MA59115 A1 MA 59115A1 MA 59115 A MA59115 A MA 59115A MA 59115 A MA59115 A MA 59115A MA 59115 A1 MA59115 A1 MA 59115A1
Authority
MA
Morocco
Prior art keywords
protein
glutamine residue
camptothecin
drug conjugates
camptothecin analogues
Prior art date
Application number
MA59115A
Other languages
French (fr)
Inventor
Amy Han
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority claimed from PCT/US2021/041304 external-priority patent/WO2022015656A1/en
Publication of MA59115A1 publication Critical patent/MA59115A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des conjugués protéine-médicament et des compositions de ceux-ci qui sont utiles, par exemple, pour administrer spécifiquement à une cible des fractions thérapeutiques, par exemple des analogues de camptothécine et/ou des dérivés. Dans certains modes de réalisation, l'invention concerne des procédés spécifiques et efficaces pour produire des constructions protéine-médicament (par exemple, des conjugués anticorps-médicament) à l'aide d'une combinaison de transglutaminase et de techniques de 1,3-cycloaddition. L'invention concerne des analogues de camptothécine, des conjugués anticorps-médicament, ainsi que des compositions qui contiennent des anticorps modifiés par glutaminyle et des charges utiles analogues de camptothécine.Disclosed herein are protein-drug conjugates and compositions thereof which are useful, for example, for target-specific delivery of therapeutic moieties, eg, camptothecin analogs and/or derivatives. In certain embodiments, the invention relates to specific and efficient methods for producing protein-drug constructs (eg, antibody-drug conjugates) using a combination of transglutaminase and 1,3- cycloaddition. Disclosed are camptothecin analogs, antibody-drug conjugates, and compositions that contain glutaminyl-modified antibodies and camptothecin analog payloads.

MA59115A 2020-07-13 2021-07-12 Camptothecin analogues conjugated to a glutamine residue in a protein and their use MA59115A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063051172P 2020-07-13 2020-07-13
PCT/US2021/041304 WO2022015656A1 (en) 2020-07-13 2021-07-12 Camptothecin analogs conjugated to a glutamine residue in a protein, and their use

Publications (1)

Publication Number Publication Date
MA59115A1 true MA59115A1 (en) 2023-03-31

Family

ID=85793881

Family Applications (1)

Application Number Title Priority Date Filing Date
MA59115A MA59115A1 (en) 2020-07-13 2021-07-12 Camptothecin analogues conjugated to a glutamine residue in a protein and their use

Country Status (1)

Country Link
MA (1) MA59115A1 (en)

Similar Documents

Publication Publication Date Title
MX2024003180A (en) Camptothecin analogs conjugated to a glutamine residue in a protein, and their use.
MA45280B1 (en) Eribulin-based antibody-drug conjugates and methods of use thereof
MA31519B1 (en) LYOPHILIZED IMMUNOGLOBULIN COMPOSITIONS AND METHODS OF PREPARATION
CA1336496C (en) Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
MA28784B1 (en) ANTI-HER2 ANTIBODY COMPOSITION
ES2440482T3 (en) PSMA-antibody-drug conjugates
EA202091135A1 (en) HYDROPHILIC LINKERS FOR ANTI-BODY-DRUG CONJUGATE CONJUGATES
MA31617B1 (en) CYTOTOXIC AGENTS COMPRISING NOVEL TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE.
CO4940469A1 (en) ORAL COMPOSITION OF IMPROVED STABILITY INCLUDING A DERIVATIVE OF INDOLINONE AND A MIXTURE OF GLYCERIDES OR POLYETHYLENE GLYCOL ESTERS
LU93067I2 (en) BLINATUMOMAB AND ITS PHARMACEUTICALLY ACCEPTABLE DERIVATIVES (BLINCYTO)
BRPI0309868B1 (en) methods of preparing a lower conjugated fraction composition
JP2020534030A5 (en)
ATE64396T1 (en) CONJUGATED VINBLASTIN COMPOUNDS AND THEIR DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
MA50259A1 (en) Steroids and their antibody conjugates
DE69737867D1 (en) TARGETED COMBINATION IMMUNOTHERAPY FOR CANCER
EP1594542A4 (en) Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
BR0116464A (en) ether starch substituted imidazoquinolines
DE60138222D1 (en) MODULATION OF IL-2 AND IL-15 MEDIATED T ZONE LANGUAGES
BR0011448A (en) Amide Substituted Imidazoquinolines
HUP0101343A2 (en) Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
BR0109846A (en) Use of a composition comprising an antibody or antigen binding fragment thereof, and together
MA27052A1 (en) PHARMACEUTICAL COMPOSITIONS OF AMLODIPINE AND ATORVASTATIN
NZ762865A (en) Psma-targeting amanitin conjugates
PL2161283T3 (en) Compositions comprising antibodies against CD79b conjugated to a growth inhibitory agent or cytotoxic agent and methods for the treatment of tumor of hematopoietic origin
MA59115A1 (en) Camptothecin analogues conjugated to a glutamine residue in a protein and their use